Journal of Clinical Oncology, Vol 10, 428-432, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients

GM Clark, MC Mathieu, MA Owens, LG Dressler, L Eudey, DC Tormey, CK Osborne, KW Gilchrist, EG Mansour and MD Abeloff
University of Texas Health Science Center, San Antonio 78284-7884.

PURPOSE: Formalin-fixed, paraffin-embedded tissues from axillary node- negative breast cancer patients were analyzed by flow cytometry to determine the prognostic significance of DNA ploidy and S-phase fraction (SPF). PATIENTS AND METHODS: All patients were registered on a good-risk control arm of an intergroup clinical trial. They had small- to intermediate-sized (less than 3 cm), estrogen receptor (ER)-positive tumors and received no adjuvant therapy after modified radical mastectomy or total mastectomy with low axillary-node sampling. The median follow-up was 4.8 years. RESULTS: Assessable ploidy results were obtained from 92% of the 298 specimens studied (51% diploid, 49% aneuploid), and SPFs were assessable for 83% of the tumors. SPFs for diploid tumors ranged from 0.7% to 11.9% (median, 3.6%), compared with a range of 1.2% to 26.7% (median, 7.6%) for aneuploid tumors (P less than .0001). No significant differences in disease-free or overall survival were observed between patients with diploid and aneuploid tumors. Using different SPF cutoffs by ploidy status (4.4% for diploid, 7.0% for aneuploid), patients with low SPFs had significantly longer disease-free survival rates than patients with high SPFs (P = .0008). The actuarial 5-year relapse rates were 15% and 32% for patients with low (n = 142) and high SPFs (n = 105), respectively. Similar relationships between SPF and clinical outcome were observed for patients with diploid tumors (P = .053) and for patients with aneuploid tumors (P = .0012). CONCLUSION: S-phase fraction provides additional prognostic information for predicting disease-free survival for axillary node-negative breast cancer patients with small, ER-positive tumors.

This article has been cited by other articles:

				K. Amend, D. Hicks, and C. B. Ambrosone Breast Cancer in African-American Women: Differences in Tumor Biology from European-American Women. Cancer Res., September 1, 2006; 66(17): 8327 - 8330. [Abstract] [Full Text] [PDF]

				L. F. Hutchins, S. J. Green, P. M. Ravdin, D. Lew, S. Martino, M. Abeloff, A. P. Lyss, C. Allred, S. E. Rivkin, and C. K. Osborne Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Versus Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102 J. Clin. Oncol., November 20, 2005; 23(33): 8313 - 8321. [Abstract] [Full Text] [PDF]

				M. Colozza, E. Azambuja, F. Cardoso, C. Sotiriou, D. Larsimont, and M. J. Piccart Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann. Onc., November 1, 2005; 16(11): 1723 - 1739. [Abstract] [Full Text] [PDF]

				Y. Vergouwe, E. W. Steyerberg, M. J.C. Eijkemans, P. Albers, and J. D. F. Habbema Predictors of Occult Metastasis in Clinical Stage I Nonseminoma: A Systematic Review J. Clin. Oncol., November 15, 2003; 21(22): 4092 - 4099. [Abstract] [Full Text] [PDF]

				P. Malmstrom, P-O. Bendahl, P. Boiesen, N. Brunner, I. Idvall, and M. Ferno S-Phase Fraction and Urokinase Plasminogen Activator Are Better Markers for Distant Recurrences Than Nottingham Prognostic Index and Histologic Grade in a Prospective Study of Premenopausal Lymph Node-Negative Breast Cancer J. Clin. Oncol., April 1, 2001; 19(7): 2010 - 2019. [Abstract] [Full Text] [PDF]

				A. Chassevent, M.-L. Jourdan, S. Romain, F. Descotes, M. Colonna, P.-M. Martin, M. Bolla, and F. Spyratos S-Phase Fraction and DNA Ploidy in 633 T1T2 Breast Cancers: A Standardized Flow Cytometric Study Clin. Cancer Res., April 1, 2001; 7(4): 909 - 917. [Abstract] [Full Text]

				J. F. Simpson, R. Gray, L. G. Dressler, C. D. Cobau, C. I. Falkson, K. W. Gilchrist, K. J. Pandya, D. L. Page, and N. J. Robert Prognostic Value of Histologic Grade and Proliferative Activity in Axillary Node-Positive Breast Cancer: Results From the Eastern Cooperative Oncology Group Companion Study, EST 4189 J. Clin. Oncol., May 10, 2000; 18(10): 2059 - 2069. [Abstract] [Full Text] [PDF]

				Y. Nieto, P. J. Cagnoni, E. J. Shpall, X. Xu, J. Murphy, J. Vredenburgh, N. J. Chao, S. I. Bearman, and R. B. Jones A Predictive Model for Relapse in High-Risk Primary Breast Cancer Patients Treated with High-Dose Chemotherapy and Autologous Stem-Cell Transplant Clin. Cancer Res., November 1, 1999; 5(11): 3425 - 3431. [Abstract] [Full Text] [PDF]

				F. J. Esteva and G. N. Hortobagyi Integration of Systemic Chemotherapy in the Management of Primary Breast Cancer Oncologist, October 1, 1998; 3(5): 300 - 313. [Abstract] [Full Text]